TECA hybrid artificial liver support system in treatment of acute liver failure

Table 1 Clinical data of six patients with liver failure

No	M/F	Age	Diagnosis	General condition	Program of treatment	t (treatment)/h
1	M	50	Liver cir rhosis (decomp ensation) HCC, ALF	Hepatic encephalopathylethargy	Whole blood CA &TECA-BALSS	2.5
2	F	50	Post operation of cancerof biliary duct, ALF, ARF	Hepatic encephalopathylethargy	Plasma CA &TECA-BALSS	2+4
3	M	32	Hepatitis BLiver failure	Hepatic encephalopathy	Plasma CA &TECA-BALSS	2+4
4	F	43	Acute viral hepatiti sfulminant hepatic failure	Hepatic encephalopathy (stage IV)	PE and TECA-BALSS	2+4
5	M	32	Hepatitis B (decompens ation) Liver failure	Hepatic encephalopathy (stage IV)	PE and TECA-BALSS	2+5
6	F	34	Drug induced hepaticinjury, liver failure	Hepatic encephalopathy lethargy	PE and TECA-BALSS	2+5